Profile
| Metric | Value |
|---|---|
| Full Name | Avadel Pharmaceuticals plc |
| Ticker | NASDAQ: AVDL |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Specialty & Generic Drug Manufacturers |
| Country | Ireland |
| IPO | |
| Indexes | Not included |
| Website | avadel.com |
| Employees | 188 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $21.58 | |
| Price, 1D Change | +0.37% | |
| Market Cap | $2B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.71 | |
| Revenue | $169M | |
| Revenue, 1Y Change | +504.79% | |
| EPS | -$0.51 | |
| EPS, 1Y Change | +74.32% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | FLML | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$0.51 | |
| EPS Estimate | $0.28 | |
| EPS Est. Change | +154.00% | |
| Revenue | $169.12M | |
| Revenue Estimate | $277.73M | |
| Revenue Est. Change | +64.22% | |
| Current Price | $21.58 | |
| Price Target | - | $21.25 |
| Price Tgt. Change | - | -1.53% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$1.83 | -$2.00 | -9.24% | |
| -$0.49 | -$0.51 | -3.93% | |
| $0.28 | N/A | +154.00% | |
| $0.78 | N/A | +252.58% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $27.96M | $27.96M | 0.00% | |
| $168.74M | $169.12M | +0.23% | |
| $277.73M | N/A | +64.22% | |
| $359.06M | N/A | +112.32% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +174.90% | |
| Price, 3Y | +188.89% | |
| Market Cap, 1Y | +178.15% | |
| Market Cap, 3Y | +348.68% | |
| Revenue, 1Y | +504.79% | |
| Revenue, 3Y | +100.00% | |
| EPS, 1Y | +74.32% | |
| EPS, 3Y | +61.15% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $21.58 | |
| SMA 200 | $14.53 | |
| SMA 200 vs Price | -32.65% | |
| SMA 50 | $21.57 | |
| SMA 50 vs Price | -0.03% | |
| Beta | 0.71 | |
| ATR | $0.11 | |
| 14-Day RSI | 56.69 | |
| 10-Day Volatility | 1.40% | |
| 1-Year Volatility | 49.76% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $169.12M | |
| EPS | -$0.51 | |
| Gross Profit | $153.84M | |
| Gross Margin | 90.97% | |
| Operating Profit | -$42.40M | |
| Operating Margin | -25.07% | |
| Net Income | -$48.83M | |
| Net Margin | -28.87% | |
| EBITDA | -$35.57M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.00 | |
| Current Ratio | 2.75 | |
| Quick Ratio | 2.33 | |
| - | ||
| F-Score | 4 | |
| Altman Z-Score | 2.95 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 8.48 | |
| PB Ratio | 21.46 | |
| EV/EBITDA | 250.42 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $73.85M | |
| Cash & Equivalents | $51.37M | |
| Total Assets | $265.80M | |
| Current Assets | $134.21M | |
| Total Liabilities | $191.95M | |
| Current Liabilities | $48.83M | |
| Total Debt | $36.95M | |
| Short Term Debt | $582.00K | |
| Accounts Payable | $7.33M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $211.52M | |
| Operating Expenses | $196.24M | |
| Cost Of Goods Sold | $15.28M | |
| SG&A | $181.04M | |
| D&A | $2.68M | |
| Interest Expense | $0.00 | |
| Income Tax | -$247.00K |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$46.91M | |
| CFI | $51.78M | |
| CFF | $15.97M | |
| Capex | $0.00 | |
| Free Cash Flow | -$46.91M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wells Fargo | → | |
| Wells Fargo | → | |
| UBS | → | |
| Leerink Partners | → | |
| HC Wainwright & Co. | → | |
| Needham | → | |
| Jefferies | → | |
| HC Wainwright & Co. | → | |
| Wells Fargo | ||
| UBS | → |
Analyst sentiment
Institutional ownership
Screeners with AVDL
FAQ
What is the ticker symbol for Avadel Pharmaceuticals plc?
The ticker symbol for Avadel Pharmaceuticals plc is NASDAQ:AVDL
Does Avadel Pharmaceuticals plc pay dividends?
No, Avadel Pharmaceuticals plc does not pay dividends
What sector is Avadel Pharmaceuticals plc in?
Avadel Pharmaceuticals plc is in the Healthcare sector
What industry is Avadel Pharmaceuticals plc in?
Avadel Pharmaceuticals plc is in the Specialty & Generic Drug Manufacturers industry
What country is Avadel Pharmaceuticals plc based in?
Avadel Pharmaceuticals plc is headquartered in Ireland
When did Avadel Pharmaceuticals plc go public?
Avadel Pharmaceuticals plc initial public offering (IPO) was on June 7, 1996
Is Avadel Pharmaceuticals plc in the S&P 500?
No, Avadel Pharmaceuticals plc is not included in the S&P 500 index
Is Avadel Pharmaceuticals plc in the NASDAQ 100?
No, Avadel Pharmaceuticals plc is not included in the NASDAQ 100 index
Is Avadel Pharmaceuticals plc in the Dow Jones?
No, Avadel Pharmaceuticals plc is not included in the Dow Jones index
When was Avadel Pharmaceuticals plc last earnings report?
Avadel Pharmaceuticals plc's most recent earnings report was on November 4, 2025
When does Avadel Pharmaceuticals plc report earnings?
The next expected earnings date for Avadel Pharmaceuticals plc is March 2, 2026
Data Sources & References
- AVDL Official Website www.avadel.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1012477/000101247725000031/0001012477-25-000031-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1012477/000101247725000010/0001012477-25-000010-index.htm
- AVDL Profile on Yahoo Finance finance.yahoo.com/quote/AVDL
- AVDL Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/avdl